Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.
The ability of activated T lymphocytes to penetrate the extracellular matrix and migrate to target tissues was found to be related to expression of a heparanase enzyme (Naparstek, Y., I. R. Cohen, Z. Fuks, and I. Vlodavsky. 1984. Nature (Lond.). 310:241-243; Savion, N., Z. Fuks, and I. Vlodavsky. 1984. J. Cell. Physiol. 118:169-176; Fridman, R., O. Lider, Y. Naparstek, Z. Fuks, I. Vlodavsky, and I. R. Cohen. 1987. J. Cell. Physiol. 130:85-92; Lider, O., J. Mekori, I. Vlodavsky, E. Baharav, Y. Naparstek, and I. R. Cohen, manuscript submitted for publication). We found previously that heparin molecules inhibited expression of T lymphocyte heparanase activity in vitro and in vivo, and administration of a low dose of heparin in mice inhibited lymphocyte traffic and delayed-type hypersensitivity reactions (Lider, O., J. Mekori, I. Vlodavsky, E. Baharav, Y. Naparstek, and I. R. Cohen, manuscript submitted for publication). We now report that treatment with commercial or chemically modified heparins at relatively low doses once daily (5 micrograms for mice and 20 micrograms for rats) led to inhibition of allograft rejection and the experimental autoimmune diseases adjuvant arthritis and experimental autoimmune encephalomyelitis. Higher doses of the heparins were less effective. The ability of chemically modified heparins to inhibit these immune reactions was associated with their ability to inhibit expression of T lymphocyte heparanase. There was no relationship to anticoagulant activity. Thus heparins devoid of anticoagulant activity can be effective in regulating immune reactions when used at appropriate doses.
Lider
O
O
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Baharav
E
E
Mekori
Y A
YA
Miller
T
T
Naparstek
Y
Y
Vlodavsky
I
I
Cohen
I R
IR
D000107:Acetylation; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D055598:Chemical Phenomena; D002621:Chemistry; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019763:Heparin Lyase; D007114:Immunization; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000276:immunology; D011133:Polysaccharide-Lyases / Q000037:antagonists & inhibitors; D051381:Rats; D011917:Rats, Inbred Lew; D013431:Sulfates; D013601:T-Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000276:immunology
D000942:Antigens, Bacterial; D013431:Sulfates; D006493:Heparin; D011133:Polysaccharide-Lyases; D019763:Heparin Lyase